T cells

[Pharmacological Research] The antitumour activity of lenvatinib in immunocompetent and immunodeficient mice was compared to determine the role of T cell immunity. The antitumour activity of T cells was analysed by cytokine production and adoptive T cell therapy.

[Journal of Immunology] Scientists examined the cellular and molecular elements that promote CD8-to-CD4 lineage conversion and the development of CI-Treg cells in mice.

[Nature Cancer] Scientists discuss the many challenges to CAR T cell therapeutic success and innovations in CAR design and T cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies.

[Haematologica] Scientists showed that endoplasmic reticulum stress contributed to intestinal tissue injury during graft-versus-host disease and could be targeted pharmacologically.

[Clinical Cancer Research] The authors conducted a Phase I trial in 36 patients with hepatocellular carcinoma who were given therapeutic C/EBPα saRNA (MTL-CEBPA) as either neoadjuvant or adjuvant treatment. MTL-CEBPA treatment in those patients caused a marked decrease in peripheral blood monocytic myeloid-derived suppressor cell numbers.

[BriaCell Therapeutics Corp.] BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, jointly announced a multi-year, non-exclusive license agreement with ImaginAb Inc., a biotechnology company focused on developing next-generation immuno oncology imaging agents and radiopharmaceutical therapies.